ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. Nov 26 special report | November 26, 2014

Download PDF Visit The Full Archive

Related Articles

Treatment research Reports Summarized; New MTX Rescues

May 6, 1977

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

April 26, 2013

CT Scanning Use, Costs, Controls Debated By NCAB

October 7, 1977

Moloney Out As Viral Oncology Chief, Names “Acting Assistant Director” Of NCI By Upton

January 6, 1978

UCSD Center Designated Comprehensive; Siteman Center In St. Louis Wins Core Grant.

August 31, 2001